Danish biotechnology firm Genmab‘s collaboration partner Janssen Biotech is planning to initiate a second Phase III trial (MMY3008) of daratumumab for the treatment of patients with multiple myeloma.

Scheduled to start in the first half of 2015, the trial is designed to compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone for patients who are not considered candidates for stem cell transplantation (SCT).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Daratumumab, a human CD38 monoclonal antibody with broad-spectrum killing activity, targets the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.

The company said that the first Phase III trial in front-line multiple myeloma was announced in July and is expected to start towards the end of this year.

The trial will enrol about 700 newly diagnosed, chemotherapy naïve multiple myeloma patients ineligible for SCT.

See Also:

"The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for daratumumab."

During the trial, patients will be randomised to receive either daratumumab combined with lenalidomide (an immunomodulatory agent) and dexamethasone (a corticosteroid) or lenalidomide and dexamethasone alone.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint of the randomised, open-label, multicentre Phase III trial is progression free survival (PFS).

Genmab CEO Jan van de Winkel said: "This new study of daratumumab in front-line multiple myeloma is part of the extensive development plan created under our collaboration with Janssen Biotech for our CD38 antibody daratumumab."

According to the company, daratumumab may also have potential in other cancers on which CD38 is expressed, including diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, acute lymphoblastic leukaemia, plasma cell leukaemia, acute myeloid leukaemia, follicular lymphoma and mantle cell lymphoma.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for daratumumab.

In August 2012, Janssen Biotech secured an exclusive worldwide license to develop and commercialise daratumumab for Genmab.